Exploring the Influence of Genetic Vulnerability to Neurodevelopmental Disorders on Antipsychotic Efficacy in Schizophrenia: Insights from a Postmortem Brain Analysis - Summary - MDSpire
Advertisement
Exploring the Influence of Genetic Vulnerability to Neurodevelopmental Disorders on Antipsychotic Efficacy in Schizophrenia: Insights from a Postmortem Brain Analysis
To investigate the relationship between genetic risks for ADHD and ASD and clinical symptoms, specifically focusing on antipsychotic responsiveness in patients with schizophrenia.
Key Findings:
The ARS of positive symptoms showed a suggestive negative correlation with ADHD-PRS and a positive correlation with ASD-PRS, although these associations did not survive multiple testing correction.
No correlation was found between ARS of general psychopathology or negative symptoms and either PRS.
Identified 1,773 differentially expressed genes (DEGs) related to neuropsychiatric disorders, enriched in neuronal and mitochondrial pathways.
Interpretation:
Genomic risk for neurodevelopmental disorders may influence antipsychotic responsiveness in schizophrenia, indicating potential molecular markers for this phenotype that warrant further exploration.
Limitations:
Limited sample size restricts the generalizability of findings, particularly in terms of the robustness of the correlations observed.
Exploratory nature of the study requires further validation in larger cohorts to confirm the findings.
Conclusion:
Further investigation is needed to confirm the findings and explore the implications of genetic vulnerability in schizophrenia treatment, particularly focusing on specific molecular pathways.
